FLNA

0.641314.52%
CN

Claude Nicaise

Independent Chairman

Dr. Claude Nicaise, M.D. serves as Independent Director of Filana Therapeutics, Inc. (formerly known as Cassava Sciences, Inc.) since 2024 and served as its Director since December 8, 2023 until 2024 and serves as its Independent Chairman since September 2024. Dr. Nicaise was a Senior Vice President of Strategic Development and Global Regulatory Affairs at Alexion Claude Nicaise, M.D. has served as a director since December 2023. Dr. Nicaise has held clinical/regulatory leadership roles that have resulted in 14 new drug approvals in various diseases areas, including neuroscience. Dr. Nicaise was an Independent Director at Chemomab Therapeutics Ltd. since March 16, 2021 until May 29, 2026. Dr. Nicaise had been Member of the Scientific Advisory Board at Ovid Therapeutics Inc. since June 2023 until 2023. He served as Head of Rare Disease Strategy at Ovid Therapeutics Inc until July 2021 and served as its Head of Research and Development since July 2021 and served as its Head of Strategic Orphan Regulatory Affairs since 2015. Dr. Nicaise served as an Executive Vice President of Clinical Development & Regulatory Affairs at Formula Pharmaceuticals, Inc. Dr. Nicaise served as Senior Vice President of Strategic Product Development & Global Regulatory Affairs at Alexion Pharmaceuticals, Inc. since July 2008 until 2014, where he managed all regulatory activities and co-managed development programs. He is a Director of Gain Therapeutics, Inc. since January 2021. He is the owner and Founder of Clinical Regulatory Services. Dr. Nicaise has regulatory strategy expertise to the orphan diseases specialist. From 1983 to 2008. Dr. Nicaise served in various positions of increasing responsibility at Bristol-Myers Squibb, where he held numerous senior management roles, including Vice-President of Global Development, Vice-President Worldwide Regulatory Science and Strategy and Oncology, Infectious Disease and NeuroScience, Executive Director of Infectious Diseases Clinical Research; and Director of Clinical Cancer Research. During his time with Bristol-Myers Squibb. Dr. Nicaise oversaw the approvals of numerous treatments for cancer, schizophrenia and infectious diseases, including Tequin (bacterial infections), Erbitux (cancer), Abilify (schizophrenia) and Reyataz (HIV). Before joining Bristol-Myers Squibb. Dr. Nicaise also worked as a Medical Advisor in Oncology at Bristol Benelux Laboratories and as an Oncology Consultant at the Braine-l'Alleud Waterloo Hospital in Brussels, Belgium. Dr. Nicaise has been a Director of Sarepta Therapeutics, Inc. since June 2015. He has been Independent Director of Minoryx Therapeutics s.l. since February 10, 2017. Dr. Nicaise is the author of more than 60 research articles published in peer-reviewed journals and is a member of several professional medical associations, including the American Society of Clinical Oncology, the European Society for Medical Oncology, the American Society for Microbiology and the American Society of Hematology. Dr. Nicaise holds an M.D. and a degree in Internal Medicine, Clinical Oncology, from the Universite libre de Bruxelles in Belgium. Dr. Nicaise has significant experience in the pharmaceuticals sector, including in clinical and regulatory affairs.

Positions